{
    "nct_id": "NCT00481520",
    "title": "A Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) Trial of Multiple Ascending Fixed Doses of SAM-531 in Subjects With Mild to Moderate Alzheimer's Disease.",
    "status": "COMPLETED",
    "last_update_time": "2009-09-28",
    "description_brief": "The primary purpose of the study is to assess whether SAM-531, an investigational drug, is safe and well tolerated, compared with placebo (a medically inactive substance), in subjects with mild to moderate Alzheimer's disease.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "N/A",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "SAM-531 (cerlapirdine; PF-05212365; WAY-262,531)"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: SAM-531 is the investigational drug named in the protocol. Literature identifies SAM-531 as cerlapirdine (PF-05212365), a selective, potent antagonist of the 5-HT6 (serotonin 6) receptor; 5-HT6 antagonists have been developed as symptomatic treatments to improve cognition in Alzheimer\u2019s disease rather than as disease-modifying biologics. \ue200cite\ue202turn0search5\ue202turn0search10\ue201.",
        "Act: The study title and description show a randomized, double-blind, placebo-controlled safety/tolerability and PK/PD trial in mild\u2013moderate AD, consistent with clinical development of a small-molecule symptomatic cognitive agent rather than a biologic targeting amyloid or tau. Clinical trial records for SAM-531 (listed under these NCT entries) confirm multiple Phase 1/2 studies of this compound in AD. \ue200cite\ue202turn0search0\ue202turn0search1\ue202turn0search6\ue201.",
        "Reflect: Given SAM-531/cerlapirdine is a small-molecule 5-HT6 receptor antagonist (not a monoclonal antibody, vaccine, or direct anti-amyloid/tau agent) and 5-HT6 antagonists are intended to improve cognition/symptoms, the correct category is 'cognitive enhancer'. No information in the provided description indicates a disease-modifying mechanism or a neuropsychiatric-targeted indication, so the classification is consistent. \ue200cite\ue202turn0search5\ue202turn0search8\ue201."
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The investigational compound SAM-531 (cerlapirdine; PF-05212365; WAY-262,531) is a selective, potent antagonist of the 5-HT6 (serotonin 6) receptor \u2014 a neurotransmitter GPCR. 5-HT6 antagonists are developed as symptomatic cognitive enhancers rather than disease-modifying anti-amyloid or anti-tau agents. \ue200cite\ue202turn0search4\ue202turn0search1\ue202turn0search7\ue201",
        "Act: Extracted details \u2014 drug name/synonyms: SAM-531 / cerlapirdine / PF-05212365 / WAY-262,531; mechanism: selective 5-HT6 receptor antagonism; clinical context: tested as a symptomatic cognitive agent in mild\u2013moderate AD (Phase 1/2 PET and PK/PD studies listed). Based on this mechanism (modulation of a neurotransmitter receptor), assign CADRO category D) Neurotransmitter Receptors. \ue200cite\ue202turn0search0\ue202turn0search4\ue201",
        "Reflect: This classification fits because the target is a serotonin (5-HT6) receptor \u2014 a neurotransmitter receptor \u2014 and the trial is a symptomatic cognitive-enhancer development program, not a disease-modifying anti-amyloid/tau or multi-target biologic. No evidence in the description indicates a different CADRO domain, so D) is the most specific match. \ue200cite\ue202turn0search7\ue202turn0search5\ue201",
        "Web search results (key sources supporting the above): 1) TargetMol product/compound page identifying cerlapirdine (SAM-531; PF-05212365; WAY-262,531) as a selective, potent 5-HT6 receptor antagonist. \ue200cite\ue202turn0search4\ue201 2) MedChemExpress product/summary page describing cerlapirdine (SAM-531) as a selective 5-HT6 antagonist developed for Alzheimer\u2019s disease research. \ue200cite\ue202turn0search1\ue201 3) PubMed study (ADME/metabolism) describing cerlapirdine (SAM-531, PF-05212365) and noting 5-HT6 antagonists in clinical development for symptomatic treatment of AD. \ue200cite\ue202turn0search7\ue201 4) Adis/clinical-trial profile noting PF-05212365 (SAM-531) clinical studies including PET receptor-occupancy and Phase I trials in the AD context. \ue200cite\ue202turn0search0\ue201"
    ]
}